

RECEIVED  
CENTRAL FAX CENTERAPR. 9 2004  
**OFFICIAL**

Docket No. 4680

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Group Art Unit: To be assigned

Ramstad et al.

Serial No.: 10/661,231

Examiner: To be assigned

Filed: September 12, 2003

For: **LOADING FEATURES FOR CHANNEL  
ARRAY**

## CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being facsimile transmitted to the  
United States Patent and Trademark Office, Fax no. 703-672-9306 on:April 7, 2004

Date of Transmission

  
Cheri GómezINFORMATION DISCLOSURE STATEMENTCommissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (listed on the attached Form PTO-1449) of which they are aware, which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement:

(a) [ ] accompanies a new patent application submitted herewith.

(b) [ ] is filed within three months after the filing date of the application or within three months after the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491.

64207\_1

Page 2

(c) [X] as far as is known to the undersigned, is filed before the mailing date of a first Office action on the merits.

(d) [ ] as far as is known to the undersigned, is filed before the mailing date of a first Office action after the filing of a request for continued examination under § 1.114.

(e) [ ] is filed after the first Office Action and more than three months after the application's filing date or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final action under §1.113, a notice of allowance under §1.311, whichever occurs first, and is accompanied by either the fee (\$180) set forth in 37 CFR §1.17(p) or a certification as specified in 37 CFR §1.97(e), as checked below. Should any fee be due, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 01-2213 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement. Any deficiency or overpayment should be charged or credited to this deposit account. A duplicate of this sheet is enclosed.

(f) [ ] is filed after the mailing date of either a final rejection or a notice of allowance, but on or before the payment of the issue fee, and is accompanied by the fee (\$180) set forth in 37 CFR §1.17(i)(1) and a certification as specified in 37 CFR §1.97(e), as checked below. **This document is to be considered as a petition requesting consideration of the information disclosure statement.** The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 01-2213 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement. Any deficiency or overpayment should be charged or credited to this deposit account. A duplicate of this sheet is enclosed.

[If either of boxes (e) or (f) is checked above, the following "certification" under 37 CFR §1.97(e) may need to be completed.] The undersigned certifies that:

[ ] Each item of information contained in the information disclosure statement was first cited in a communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.

[ ] No item of information contained in this information disclosure statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this information disclosure statement.

Page 3

A copy of the items on PTO/SB/08A that are not United States Patent Documents:

are supplied herewith.


are not supplied because they were previously cited by or submitted to the Office in prior application Serial No. \_\_\_\_\_, filed \_\_\_\_\_ and relied upon in this application for an earlier filing date under 35 USC §120.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,

Date: 3/8/04



Phil N. Makrogiannis  
Reg. No. 47,766  
Attorney for Applicants

**Correspondence Address**

Customer Number 22896  
Applied Biosystems Division  
Applera Corporation  
850 Lincoln Centre Drive  
Foster City, CA 94404  
(650) 638-6492 (Phone)  
(650) 638-6677 (Fax)

Please type a plus sign (+) inside this box. →

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/661,231
				Filing Date	September 12, 2003
				First Named Inventor	Ramstad, Paul
				Group Art Unit	TBA
				Examiner Name	TBA
				Attorney Docket No.	4680
Sheet	1	of	2		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments or the amount of time you are allowed to complete this form should be sent to the Office of Information and Technology, U.S. Department of Health and Human Services, 200 Independence Avenue SW, Washington, DC 20201.

APR. 7. 2004 4:40PM APPLIED BIOSYSTEMS LEGAL2

NO. 3956 P. 6

PTO/SB/08A (08-001)

Please type a plus sign (+) inside this box. →

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p><i>(Use as many sheets as necessary)</i></p>				<p><b>Complete If Known</b></p>	
Sheet	2	of	2	Application Number	10/661,231
				Filing Date	September 12, 2003
				First Named Inventor	Ramstad, Paul
				Group Art Unit	TBA
				Examiner Name	TBA
				Attorney Docket No.	4680

**OTHER ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

**\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Oklahoma Department of Transportation, 1000 Lincoln Boulevard, Suite 1000, Oklahoma City, OK 73102.

APR. 7. 2004 4:38PM

APPLIED BIOSYSTEMS LEGAL2



An Applera Corporation Business  
850 Lincoln Centre Drive  
Foster City, CA 94404-1128 U.S.A.  
www.appliedbiosystems.com

NO. 3956 P. 1  
RECEIVED  
CENTRAL FAX CENTER

APR. 09 2004

OFFICIAL

## FAX TRANSMITTAL

Date: April 7, 2004

To: Commissioner for Patents

Company: U.S. Patent and Trademark Office

Fax No.: 703-872-9306

From: Cheri Gomez for Phil N. Makrogiannis, Reg. No. 47,766

Legal Department

Fax No.: 650-638-6677

Telephone No.: 650-638-5039

Email: gomezcn@applera.com

Subject: Information Disclosure Statement  
U.S. Patent Application No. 10/661,231

Filing Date: September 12, 2003

In re Application of: RAMSTAD et al.

Title: LOADING FEATURES FOR CHANNEL ARRAY

Our File: 4680 US

No. of pages (including cover sheet): 9

---

Message:

Attached is an Information Disclosure Statement for the above-identified patent application.

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 703-872-9306 on April 7, 2004.

---

Cheri Gomez

Name

---

A handwritten signature of Cheri Gomez in black ink.

Signature

Note: The information contained in this facsimile message may be attorney-client privileged and may contain confidential information intended only for the use of the individual named above, and others who have been specifically authorized to receive it. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please destroy the copy and return the original transmission to me by mail without making a copy. Thank you.